Advertisement

Loading...

InnoCan Pharma Corporation

INNO.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
$6.66
$0.07(1.06%)
Canadian Market is Open • 15:15

InnoCan Pharma Corporation (INNO.CN) Stock Competitors & Peer Comparison

See (INNO.CN) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
INNO.CNCA$6.66+1.06%30M-5.79-CA$1.15N/A
CURA.CNCA$5.22+9.21%4.1B-6.07-CA$0.86N/A
BHC.TOCA$7.61+8.40%2.8B12.97CA$0.58N/A
CURA.TOCA$3.03+14.77%2.3B-6.82-CA$0.44N/A
VRNO.CNCA$6.32+6.76%2.2B-5.40-CA$1.17N/A
GTII.CNCA$8.90+13.09%2.1B13.25CA$0.67N/A
CRON.TOCA$3.56+4.71%1.3B-117.33-CA$0.03N/A
TRUL.CNCA$7.78+10.35%1.3B-9.66-CA$0.80N/A
TLRY.TOCA$9.30+11.38%908.2M-0.27-CA$32.71N/A
TER.CNCA$2.38-0.42%804.8M-1.33-CA$1.79N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

INNO.CN vs CURA.CN Comparison April 2026

INNO.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INNO.CN stands at 30M. In comparison, CURA.CN has a market cap of 4.1B. Regarding current trading prices, INNO.CN is priced at CA$6.66, while CURA.CN trades at CA$5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INNO.CN currently has a P/E ratio of -5.79, whereas CURA.CN's P/E ratio is -6.07. In terms of profitability, INNO.CN's ROE is -0.72%, compared to CURA.CN's ROE of -0.28%. Regarding short-term risk, INNO.CN is less volatile compared to CURA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for INNO.CN.Check CURA.CN's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions